Eli Lilly – Global Leader in Innovative Pharmaceuticals
Eli Lilly
Eli Lilly and Company is an American pharmaceutical company founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. It is headquartered in Indianapolis, Indiana, and its shares trade on the New York Stock Exchange (NYSE).
Lilly was one of the first companies to produce insulin industrially: from 1923 it sold Iletin, the first commercially available insulin in the US. In 1982 it launched Humulin, the first human insulin made with recombinant DNA technology. Its other well-known medicines include the antidepressant Prozac (fluoxetine), Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for breast cancer and Kisunla (donanemab) for Alzheimer's disease.
The company's main areas are diabetes and obesity, oncology, immunology and neuroscience. Mounjaro (tirzepatide), the first dual GIP and GLP-1 receptor agonist, was approved in the US for type 2 diabetes in May 2022; as Zepbound, tirzepatide has been used for weight loss since 2023. In April 2026 the FDA approved Foundayo (orforglipron), a GLP-1 receptor agonist pill for weight management that can be taken at any time of day without food or water restrictions.
Unifarm carries Eli Lilly medicines: Mounjaro and Mounjaro KwikPen (tirzepatide) in strengths from 2.5 to 15 mg, and Foundayo (orforglipron) in strengths from 0.8 to 17.2 mg — see the full list below.